Novartis appoints John Tsai head of global drug development and chief medical officer
BASEL, Switzerland — Novartis has appointed John Tsai as the company’s head of global drug development (GDD) and chief medical officer and will begin his new role on May 1. Tsai will report to Novartis CEO Vas Narasimhan and will become a member of the company’s executive committee. Tsai succeeds Narasimhan who became CEO of
